Biogen Idec (Nasdaq: BIIB) and Elan Corp PLC (NYSE: ELN) said two-year data from the AFFIRM Phase III monotherapy trial ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE